Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3A | P49840 | 1/20 | 0.31 |
| ▸ | GSK3B | P49841 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23519914 | 0.71 | MGLL (0.33) | GSK3AGSK3BMGLLKDM4ENPC1 | |
| SCHEMBL23052619 | 0.68 | GSK3A (0.35) | GSK3AGSK3BMGLLKDM4ENPC1 | |
| SCHEMBL24285588 | 0.67 | GSK3A (0.30) | GSK3AGSK3BMGLL | |
| SCHEMBL4016737 | 0.67 | ALDH1A1 (0.33) | GSK3AGSK3BMGLLALDH1A1 | |
| SCHEMBL14608278 | 0.67 | ALDH1A1 (0.38) | GSK3AGSK3BMGLLKDM4ENPC1 | |
| SCHEMBL4005408 | 0.65 | ACHE (0.49) | MGLLALDH1A1 | |
| SCHEMBL19120576 | 0.65 | — | — | |
| SCHEMBL720415 | 0.65 | MAOA (0.46) | GSK3AGSK3BMGLL | |
| SCHEMBL181251 | 0.61 | — | — | |
| SCHEMBL23482669 | 0.61 | GSK3A (0.32) | GSK3AGSK3BMGLLKDM4ENPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190099506-A1 | METHODS AND COMPOSITIONS FOR DEUTERATED BIOLOGICS | BRISTOL-MYERS SQUIBB COMPANY | 2019-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190099506-A1 | METHODS AND COMPOSITIONS FOR DEUTERATED BIOLOGICS | CD22, DSP, CD44 | GSK3A 1791/4885GSK3B 1393/4885MGLL 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.